Добірка наукової літератури з теми "Periodontitis; oral mucositis; head and neck radiotherapy"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Periodontitis; oral mucositis; head and neck radiotherapy".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Periodontitis; oral mucositis; head and neck radiotherapy"
1
Khaw, Arlene, Sharon Liberali, Richard Logan, Dorothy Keefe, and P. Mark Bartold. "Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy: a pilot study." Supportive Care in Cancer 22, no. 8 (March 20, 2014): 2119–25. http://dx.doi.org/10.1007/s00520-014-2186-3.
Повний текст джерела
2
Bodard, Anne-Gaëlle, Abdelbaste Hrifach, Samuel Salino, Matthieu Fabris, Aline Desoutter, Pascal Pommier, and Jérôme Fayette. "Incidence of mucositis in patients with head and neck squamous cell carcinoma treated with radiotherapy plus cetuximab: a pilot study." Médecine Buccale Chirurgie Buccale 18, no. 3 (July 5, 2012): 181–85. http://dx.doi.org/10.1051/mbcb/2012020.
Повний текст джерела
3
Labrosse, Géraldine, Nicolas Graillon, Eric Maladiere, Romain Lan, and Fabrice Campana. "Update of photobiomodulation in oral mucositis: a systematic review." Journal of Oral Medicine and Oral Surgery 28, no. 4 (2022): 40. http://dx.doi.org/10.1051/mbcb/2022016.
Повний текст джерелаАнотація:
Introduction: Oral mucositis (OM) is a common side effect of radiotherapy (RT) or radio-chemotherapy (RT/CT) for head and neck cancers. It causes lesions leading to impairment of the quality of life, dysphagia, pain, and in up to 20% of cases, a dosimetry concession, decreasing local tumor control, thereby impacting the survival rate. Positive results of photobiomodulation (PBM) to treat it have been reported in the literature. PBM has multiple parameters (type of laser, emission mode, number of sessions to be performed, wavelength, power, energy, fluence, exposure time, number of points) making it difficult to implement in clinical practice. Materials and methods: A literature search strategy was applied in Medline by selecting articles published between 2010 and 2020 to answer the following research question: “In patients treated with RT or RT/CT, what is the place of PBM in the management of OM?”, in accordance with PICO (patient, intervention, comparison and outcomes) criteria. The inclusion criteria were all original articles (clinical cases and clinical studies) which answered the research question. Meta-analyses, systematic reviews of the literature and journals, animal or in vitro studies, studies published in a language other than French or English, and full-text articles not accessible via inter-university credits were excluded. Results: Seventeen articles were included, representing 1576 patients. The PBM was intraoral in 16 papers and combined intra- and extra-oral emission in 1 paper. InGaAlP diode laser and HeNe laser significantly reduced OM compared with placebo in 62.5% and 75% of the studies, respectively. Pain reduction was poorly or not documented and when it was, it did not correlate with the reduction of analgesics. Temporary or permanent interruption of radiotherapy was also poorly documented. Discussion: The MASCC/ISOO (2019) report is an important step forward to establish a reproducible protocol for PBM, which as our results show, is heterogeneous in use. Our results showed that the studies started PBM on the first day of RT, using a wavelength of 660 nm for diode laser and 632.8 nm for HeNe laser. However, there is no scientific evidence vis-à-vis the values for power, energy, fluence, exposure time, or number of points. Although PBM appears to be effective in reducing OM scores, its effectiveness on improving patient quality of life, pain, painkiller consumption, compliance with treatment and the occurrence of complications remains to be defined. The relationship between PBM and survival rate was not an objective of this work. We found that of the 17 articles, 15 stated that they did not illuminate the tumor site during PBM sessions. Conclusion: The main objective of this work was to determine the place of PBM in the treatment of OM. Overall, the results on OM scores were favorable in almost ¾ of the studies. Despite its efficacy, the questions of the adjustment of the parameters of PBM, the harmonization on OM scale and its safety on carcinologic recurrence remain to be studied. In view of the lack of comparability of studies and the lack of reported data, studies that harmonize endpoints and follow-up criteria are needed to establish a standard protocol.
4
Nicolatou-Galitis, Ourania, Konstantinos Dardoufas, Panagiotis Markoulatos, Anastasia Sotiropoulou-Lontou, Konstantinos Kyprianou, Georgia Kolitsi, George Pissakas, et al. "Oral pseudomembranous candidiasis, herpes simplex virus-1 infection, and oral mucositis in head and neck cancer patients receiving radiotherapy and granulocyte-macrophage colony-stimulating factor (GM-CSF) mouthwash." Journal of Oral Pathology & Medicine 30, no. 8 (September 2001): 471–80. http://dx.doi.org/10.1034/j.1600-0714.2001.030008471.x.
Повний текст джерела
5
Bajracharya, Barsha, Subrata Bhattacharyya, and Pratibha Poudel. "Evaluation of oral mucositis in oral cancer patients undergoing radiotherapy." Journal of Chitwan Medical College 8, no. 2 (June 30, 2018): 6–9. http://dx.doi.org/10.3126/jcmc.v8i2.23730.
Повний текст джерелаАнотація:
Introduction: The present study was conducted to evaluate oral mucositis in oral cancer patients receiving head and neck radiotherapy.
Methods: Sixty oral cancer patients who had received at least 40 grays of radiation were included in the study. Mucositis was scored by oroscopy using WHO scale. Grades of mucositis were then compared with total dose of radiation received by the patients.
Results: The cases were receiving the mean cumulative dose of standard radiation therapy of 2Gy per fraction, 5 fractions per week. All the patients developed oral mucositis. The majority had grade I mucositis, followed by grade III, II and IV. The grade of mucositis was directly proportional to the dose of radiation exposure.
Conclusion: Oral mucositis occurs among all the patients undergoing head and neck radiotherapy and grade of mucositis is proportional to the dose of radiation exposure.
6
Vissink, A., J. Jansma, F. K. L. Spijkervet, F. R. Burlage, and R. P. Coppes. "Oral Sequelae of Head and Neck Radiotherapy." Critical Reviews in Oral Biology & Medicine 14, no. 3 (May 2003): 199–212. http://dx.doi.org/10.1177/154411130301400305.
Повний текст джерелаАнотація:
In addition to anti-tumor effects, ionizing radiation causes damage in normal tissues located in the radiation portals. Oral complications of radiotherapy in the head and neck region are the result of the deleterious effects of radiation on, e.g., salivary glands, oral mucosa, bone, dentition, masticatory musculature, and temporomandibular joints. The clinical consequences of radiotherapy include mucositis, hyposalivation, taste loss, osteoradionecrosis, radiation caries, and trismus. Mucositis and taste loss are reversible consequences that usually subside early post-irradiation, while hyposalivation is normally irreversible. Furthermore, the risk of developing radiation caries and osteoradionecrosis is a life-long threat. All these consequences form a heavy burden for the patients and have a tremendous impact on their quality of life during and after radiotherapy. In this review, the radiation-induced changes in healthy oral tissues and the resulting clinical consequences are discussed.
7
Dewi, Tenny Setiani, Yannie Febby Lefaan, Sri Susilawati, Adji Kusumadjati, and Erry Mochamad Arief. "<strong>Correlation analysis between risk factors and mucositis oral in head and neck cancer patients undergoing radiotherapy</strong>." Padjadjaran Journal of Dentistry 34, no. 2 (July 31, 2022): 95. http://dx.doi.org/10.24198/pjd.vol34no2.39165.
Повний текст джерелаАнотація:
ABSTRACTIntroduction: Radiotherapy is a cancer therapy that uses ionizing radiation to damage cancer cells. Ionizing radiation in the head and neck area can disrupt the function and integrity of the oral mucosa and cause oral mucositis. In Bandung, the prevalence and risk factors of oral mucositis in head and neck cancer (HNC) patients undergoing radiotherapy have not been studied. Some textbooks claim that the prevalence of radiotherapy-induced oral mucositis in HNC patients occurs at almost 100%. Various risk factors associated with oral mucositis have been studied, giving significantly different results. This research analyzes the correlation between risk factors and mucositis oral in head and neck cancer patients undergoing radiotherapy. Methods: This research is a cross-sectional retrospective study with secondary data from medical records of HNC patients at RSHS from January 2015 until December 2019. A consecutive sampling method was used to collect the data that match the Inclusion criteria, including diagnosis of HNC(ICD-10), receiving radiotherapy from the first cycle until the last cycle; having a complete medical record following variables (location of HNC coding by ICD-10, gender, age, education level, smoking habit, the cycle of radiotherapy, oral treatment, body mass index, and comorbid disease). All data were then analyzed using Spearman correlation. Result: 171 medical records showed 59 patients had oral mucositis after radiotherapy. 26.9% male and 7.6% female, with susceptible age 40-60 years. Analysis of the Spearman correlation, there is a significant relationship between body mass index (BMI) (ρ = 0,001), smoking habits (ρ = 0,001), and radiotherapy cycles (ρ = 0.001). Conclusion: There is a correlation between risk factors of oral mucositis in HNC patients undergoing radiotherapy in RSHS, including body mass index (BMI), smoking habits, and radiotherapy cycles.Keywords: Head and neck cancer; oral mucositis; prevalence; risk factor; retrospective study
8
Traktama, Dewi Oktafia, and Irna Sufiawati. "Oral mucositis severity in patient with head and neck cancer undergoing chemotherapy and/or radiotherapy." Majalah Kedokteran Gigi Indonesia 4, no. 1 (December 19, 2018): 52. http://dx.doi.org/10.22146/majkedgiind.33709.
Повний текст джерелаАнотація:
Oral mucositis is an inflammatory process and ulcerative of the oral mucosa due to chemotherapy and/or radiotherapy. The incidence and severity of oral mucositis might be influenced by a variety of risk factors, related to the host and treatment of the cancer. This aim of the case report is to evaluate risk factors that affect the severity of oral mucositis in two patients with nasopharyngeal cancer undergoing chemotherapy and/or radiotherapy. The first case, oral mucositis grade III and oral candidiasis to a 54-year old woman undergoing 16 times radiotherapy for nasopharyngeal cancer stage IV. The second case, oral mucositis grade I and oral candidiasis were found in a 55-year old man suffering from nasopharyngeal cancer stage IV who has been treated 10 times with chemotherapy and radiotherapy. Both patients had a similar age range and cancer stage. The differences of severity oral mucositis in both cases were suspected due to the host factors-related that are gender and nutritional status. In addition, intra-oral condition (poor oral hygiene, xerostomia), smoking habits and patient compliance may also affect the severity of oral mucositis in the second case. Treatment factors such as the type, dose and duration of chemotherapy t, might also affect the severity in both cases. Both patients were given chlorhexidine gluconate 0.2%, nystatin oral suspension, vitamin B12, and folic acid for treating oral mucositis. In conclusion, the understanding of risk factors oral mucositis is deemed necessary to control the severity and to provide an appropriate management to improve the quality of patients’ life.
9
Arumsadu, Annisa Gustiasti, Niluh Ringga Woroprobosari, Rina Kartika Sari, and Rochman Mujayanto. "POTENTIAL OF OZONE WATER TO REDUCE THE SEVERITY OF ORAL MUCOSITIS IN PATIENTS POST HEAD AND NECK RADIOTHERAPY." Jurnal Medali 3, no. 1 (September 28, 2021): 12. http://dx.doi.org/10.30659/medali.v3i1.16965.
Повний текст джерелаАнотація:
Background: Cancer is the second leading cause of death in the world after heart disease. One type of cancer, namely head and neck cancer, can be treated with head and neck radiotherapy. Continuous radiotherapy will cause an increase in oxidative stress and free radicals and damage to the oral mucosa, one of which is oral mucositis. Giving ozone water can help reduce the degree of oral mucositis in patients. Ozone water itself has several beneficial effects such as antioxidant, anti-inflammatory, and antimicrobial. The purpose of this study was to determine the potential of ozone water in reducing the severity of oral mucositis in patients after head and neck radiotherapy.Method: Gargling treatment using ozone water in a ratio of 2:3 for 1 minute with 4 repetitions for 2 weeks showed a significant reduction in pain. Ozone used in gas or liquid form for more than 5 minutes has the potential to cause side effects on the duration of inflammation and for gas can cause infection in the respiratory tract.Conclusion: The conclusion of this review is that the administration of ozone water with a concentration of 2-4 ppm for approximately 5 minutes has the potential to cure oral mucositis due to head and neck radiotherapy
10
Verma, Anjali, Rashmi P. John, and Kirti Srivastava. "EFFECTIVENESS OF TOPICAL APPLICATION OF MIXTURE OF HONEY AND COFFEE IN RADIATION INDUCED ORAL MUCOSITIS AMONG PATIENTS WITH HEAD & NECK CANCER UNDERGOING RADIOTHERAPY AT RADIOTHERAPY DEPARTMENT OF KGMU, LUCKNOW, U.P." International Journal of Advanced Research 8, no. 10 (October 31, 2020): 55–62. http://dx.doi.org/10.21474/ijar01/11823.
Повний текст джерелаАнотація:
Background: Cancers commonly known as head and neck cancers typically begin in the squamous cells that line the moist, mucosal surfaces within the head and neck. Oral mucositis is erythematous and ulcerative lesion of the oral mucosa in patients with cancer being treated with chemotherapy/ radiation therapy in the areas of oral cavity. Objectives: To assess the grade of the oral mucositis among head & neck cancer patients receiving radiotherapy. 2. To evaluate the effectiveness of mixture of honey and coffee application on radiation induced oral mucositis among the study group. 3. To find the association between the radiation induced oral mucositis with selected demographic variables. Method: quasi experimental non randomized control group design was applied and 60 samples (30 in each group) were selected by convenience sampling technique. The mixture of honey and coffee was applied to the study group before and after 15 minutes of radiotherapy till the continuation of radiotherapy and no intervention was given in the control group. Result: The result revealed that the application of honey and coffee mixture was significantly effective on oral mucositis (p<0.001) in the study group. Conclusion: The study concluded that, application of mixture of honey and coffee is an effective method of reducing the onset and severity of oral mucositis in comparison with no intervention.
Дисертації з теми "Periodontitis; oral mucositis; head and neck radiotherapy"
1
Chan, Sze-man, and 陳詩敏. "A clinical guideline to manage radiotherapy induced oral mucositis in head and neck cancer patients." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2010. http://hub.hku.hk/bib/B44622934.
Повний текст джерела
2
Alencar, Anelise Ribeiro Peixoto. "Tratamento da mucosite oral radio e quimioinduzida: comparação entre protocolo medicamentoso convencional e tratamentos com lasers em baixa intensidade." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/85/85134/tde-01072011-131133/.
Повний текст джерелаАнотація:
Neste estudo clínico verificaram-se os efeitos do laser em baixa intensidade na prevenção e tratamento da mucosite oral radio e/ou radioquimioinduzida. Foram selecionados 31 pacientes portadores de câncer em cabeça e pescoço a serem submetidos à radioterapia ou a radioterapia em associação a quimioterapia, os quais foram distribuídos aleatoriamente em três grupos: grupo 1 (controle) tratamento medicamentoso; grupo 2 tratamento medicamentoso e laserterapia diária, a partir do início da ulceração referente à mucosite grau 2 e grupo 3 tratamento medicamentoso e laserterapia diária a ser iniciada imediatamente antes do início da radioterapia. Os parâmetros de irradiação foram: comprimento de onda de 660nm, potência de 100mW, modo de operação contínuo, aplicação pontual, energia de 2J por ponto em 30 pontos pré-determinados, sendo o tempo utilizado de 20s por ponto. O grupo controle recebeu tratamento medicamentoso que consistia no uso de um conjunto de medidas preventivas e terapêuticas para abordagem dos efeitos adversos agudos radioinduzidos. Os resultados foram avaliados, quanto à ocorrência, graus e escore de dor associados à mucosite oral, perda de massa corpórea, uso de sonda nasogástrica, necessidade de internação e interrupção do tratamento oncológico decorrentes da mucosite oral. Os resultados indicam que o protocolo de aplicação do laser em sua forma preventiva é o mais efetivo na prevenção e tratamento da mucosite oral e que seu uso diário contribuiu para o alívio da sintomatologia dolorosa colaborando para melhora da qualidade de vida do paciente oncológico.In this clinical study verified the effects of low intensity laser in the prevention and treatment of oral mucositis radio and/or chemical induced. Thirty one patients with head and neck cancer were selected before being submitted to cancer exclusive radiotherapy or radio and associated chemotherapy. The patients were distributed into three randomly groups as follows: group 1- (control) conventional medicine treatment; group 2 conventional medicine treatment and daily lasertherapy as soon as grade two oral mucositis appeared; group 3 conventional medicine treatment and daily lasertherapy to be initiated immediately before radiotherapy sessions.The irradiation parameters were: wavelength of 660nm, potency of 100mW, continuous mode, punctual application, 2J energy on thirty pre-determined 30 points, with 20s of exposure per point. The control group received medical treatment which consisted in using a set of preventive and therapeutic approach for acute radiation-induced adverse effects. Results were evaluated observing occurrence and grade of oral mucositis, score of pain, loss of body mass, use of nasogastric sound line, internment and interruption of oncologic treatment due to oral mucositis. The results showed that the preventive protocol as used was the most effective in prevention and treatment of oral mucositis and that its daily application contributed in relieving the painful symptomatology so collaborating to maintain and/or bettering the life quality of oncologic patients.
3
Andrade, Ana Paula Eufr?zio do Nascimento. "Estudo cl?nico randomizado sobre a efic?cia da polihexanida no tratamento da mucosite oral em pacientes com c?ncer de cabe?a e pesco?o." Universidade Estadual de Feira de Santana, 2016. http://localhost:8080/tede/handle/tede/549.
Повний текст джерелаАнотація:
Submitted by Jadson Francisco de Jesus SILVA (jadson@uefs.br) on 2018-01-23T22:40:05Z
No. of bitstreams: 1
ANA PAULA EUFR?ZIO.pdf: 1790027 bytes, checksum: 4b9b469a85fd902129536275d6da931f (MD5)Made available in DSpace on 2018-01-23T22:40:06Z (GMT). No. of bitstreams: 1 ANA PAULA EUFR?ZIO.pdf: 1790027 bytes, checksum: 4b9b469a85fd902129536275d6da931f (MD5) Previous issue date: 2016-08-26
Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior - CAPES
Introduction: Malignant neoplasms represent one of the main causes of morbi-mortality in Brazil and worldwide. Radiotherapy, whether associated or not with chemotherapy, is the therapeutic modality most often used for cancer of the head and neck. However, it can trigger reactions at the oral level, such as oral mucositis, the most limiting side effect, with intense pain and difficulty eating, which may require the suspension of oncologic treatment for the patient. Polyhexanide has been used effectively and safely in the treatment of acute and chronic wounds. Objectives: To describe the clinical-epidemiologic profile and investigate the efficacy of polyhexanide in the treatment of oral mucositis and pain relief, in the period of 8-15 days, among patients with cancer of the head and neck undergoing treatment with radiotherapy (whether associated or not with chemotherapy). Methods: A randomized clinical trial was conducted, parallel and double-blind, among patients with cancer of the head and neck undergoing radiotherapy treatment with or without chemotherapy, in the High Complexity Oncology Unit of Feira de Santana, Bahia, who developed oral mucositis, were 18 years of age or older and consented to participation and signed informed consent forms in the period of July 2015 to May 2016. Two equal groups were formed by random allocation?an intervention group (polyhexanide gel) and a control group (gel without polyhexanide). These groups were reevaluated after 8 and 15 days of use of the gels. Clinical exams, evaluations of the medical records, and interviews with the application of a survey instrument used in the study were approved by the Committee for Ethics in Human Subjects Research of the State University of Feira de Santana, under the number 1.074.479/2015. Statistical analysis consisted of relative and absolute frequencies, averages, medians, and standard deviation, and the p-value?considered statistically signification when <0.05?were obtained by non-parametric Friedman tests, Wilcoxon the posts with signs and Wilcoxon-Mann-Whitney. Results: The findings were presented as an article. The mean age was 59.68 years; 58.8% men; 67.6% Brown/Black, and 79.4% with an elementary school education or less. The majority of tumors (64.7%) already presented in advanced stage, and the most frequent were those of the pharynx (23.5%) and the oral cavity (20.4%). Radiotherapy associated with chemotherapy was the most used therapy. Grades III and IV of oral mucositis were the most frequent in the third and fourth weeks of radiotherapy treatment. A total of 34 individuals were accompanied, 17 in the intervention group and 17 in the control group. After a period of 8 to 15 days, statistically significant differences were observed (p<0.05) in relation to the reduction in severity of the oral mucositis and pain, between the time points of gel use in the intervention group. Conclusions: Knowledge of the clinical-epidemiologic profile of patients undergoing oncology treatment with oral mucositis is important to establish potentially effective treatments. In this study polyhexanide represented an effective therapy in the treatment of oral mucositis and relief of pain, with positive results in the first 8 days of use.
As neoplasias malignas representam uma das principais causas de morbimortalidade no Brasil e no mundo. A Radioterapia, associada ou n?o a quimioterapia, ? a modalidade terap?utica mais empregada para o c?ncer de cabe?a e pesco?o. Todavia, pode desencadear rea??es em n?vel bucal, como a mucosite oral, o efeito mais limitante, com dor intensa e dificuldades na alimenta??o, podendo requerer at? a suspens?o do tratamento oncol?gico do paciente. A polihexanida tem sido empregada no tratamento de feridas agudas e cr?nicas, com efic?cia e seguran?a. Objetivos: Descrever o perfil cl?nico-epidemiol?gico e investigar a efic?cia da polihexanida no tratamento da mucosite oral e do al?vio da dor, no per?odo de 8 e 15 dias, em pacientes com c?ncer de cabe?a e pesco?o, sob tratamento com radioterapia associada ou n?o a quimioterapia. M?todos: Realizou-se um ensaio cl?nico randomizado, paralelo e duplo cego, com todos os pacientes com c?ncer de cabe?a e pesco?o sob tratamento com radioterapia associada ou n?o a quimioterapia, na Unidade de Alta Complexidade em Oncologia de Feira de Santana, Bahia, que desenvolveram mucosite oral, tinham 18 anos ou mais de idade e aceitaram participar assinando o termo de consentimento livre e esclarecido, no per?odo de julho de 2015 a maio de 2016. Dois grupos foram igualmente formados por aloca??o aleat?ria, o de interven??o (gel de polihexanida) e o grupo controle (gel sem polihexanida), e reavaliados nos intervalos de 8 e 15 dias de uso dos g?is. Avalia??es cl?nicas, de prontu?rios e entrevistas com aplica??o de formul?rio foram aplicadas neste estudo aprovado pelo Comit? de ?tica em Pesquisa com Seres Humanos da Universidade Estadual de Feira de Santana sob o n?mero 1.074.479/2015. Para a an?lise estat?stica empregaram-se as frequ?ncias relativas e absolutas, m?dias, medianas e desvio-padr?o, e o valor de p, considerado estatisticamente significativo quando ? 0,05 foi obtido por meio dos testes n?o param?tricos de Friedman, Wilcoxon dos postos com sinais e Wilcoxon-Mann-Whitney. Resultados: Os achados foram apresentados em forma de artigo. A m?dia de idade foi de 59,68 anos; 58,8% homens; 67,6% de cor parda e 79,4% analfabetos ou com baixo grau de escolaridade. A maioria (64,7%) dos tumores j? se apresentava em est?dio avan?ado, sendo os mais frequentes os da faringe (23,5%) e cavidade oral (20,4%). A Radioterapia associada ? quimioterapia foi a terap?utica mais empregada. Graus III e IV de mucosite oral foram mais frequentes nas 3? e 4? semanas de tratamento radioter?pico. Um total de 34 indiv?duos foi acompanhado, sendo 17 do grupo de interven??o e 17 do grupo controle. Ap?s um per?odo de 8 e 15 dias, observaram-se diferen?as estatisticamente significativas (p<0,05) em rela??o a redu??o da gravidade da mucosite oral e da dor, entre os tempos de uso do gel no grupo de interven??o. Conclus?es: O conhecimento do perfil cl?nico-epidemiol?gico de pacientes em tratamento oncol?gico com mucosite oral faz-se importante para se estabelecer terap?uticas potencialmente eficazes. Neste estudo a polihexanida apresentou-se como uma terap?utica eficaz no tratamento da mucosite oral e controle da dor, com resultados positivos ainda nos primeiros 8 dias de uso.
4
Lima, Aline Gouvêa de. "Avaliação da eficácia da aplicação preventiva do laser de baixa potência em pacientes com mucosite oral induzida por radioquimioterapia." Universidade de São Paulo, 2009. http://www.teses.usp.br/teses/disponiveis/5/5155/tde-23032010-100838/.
Повний текст джерелаАнотація:
Estudo de fase III, prospectivo, aleatorizado e duplo-cego de prevenção de mucosite oral com laser de baixa potência. Foram incluídos pacientes portadores de câncer de cabeça e pescoço, tratados com radioquimioterapia. Grupo A laser 2,5 J/cm2 diariamente durante o tratamento e grupo B laser placebo. Inclusão de 75 pacientes (A/B 37/38). Grau III /IV mucosite: A/B 2a semana (4/5) P=1.0, 4a semana (4/12) P=0.04 e 6a semana (8/9) P=1.0. Interrupções da RT devido à mucosite A/B 0/6 P=0.02. Dor severa A/B 2a semana (5/5), 4a semana (8/8) e 6a semana (8/8) P=1.0. O tratamento com laser foi efetivo, tendo adiado o aparecimento da mucosite severa e reduzido as interrupções da radioterapia.Phase III, prospective, randomized, double-blind study of oral mucositis prophylaxis by low energy laser. Patients included had a diagnosis of head and neck cancer and were managed with radiochemotherapy. Arm A laser 2.5 J/cm2 daily throughout treatment and B sham laser. Inclusion of 75 patients (A/B 37/38). Grade III /IV mucositis A/B: week 2 (4/5) P=1.0, week 4 (4/12) P=0.04 and week 6 (8/9) P=1.0. Treatment breaks due to mucositis A/B 0/6 P=0.02. Severe pain A/B week 2 (5/5), week 4 (8/8) and week 6 (8/8) P=1.0. Low laser therapy was effective, delaying severe mucositis and reducing radiotherapy breaks.
5
Ribeiro, Sara Isabel Macedo. "Alterações na cavidade oral provocadas pelo tratamento de radioterapia em pacientes com cancro de cabeça e pescoço." Master's thesis, [s.n.], 2012. http://hdl.handle.net/10284/3702.
Повний текст джерелаАнотація:
Projeto de Pós-Graduação/Dissertação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Mestre em Medicina DentáriaO cancro de cabeça e pescoço representa cerca de 10% dos tumores malignos a nível mundial, e anualmente são diagnosticados sensivelmente 500.000 novos casos em todo o mundo. A nível nacional, o cancro de cabeça e pescoço é uma neoplasia maligna relativamente frequente, sendo responsável por uma taxa de mortalidade elevada. No ano de 2005 e 2006 foram registados 10286 doentes no RORENO, e destes, 1240 eram referentes à cavidade oral e pescoço, sendo as principais localizações na glândula tiroideia, seguida da laringe, esófago, boca (que inclui a gengiva, o pavimento da boca, palato e o trígono retromolar), língua, amígdala, lábio, hipofaringe, nasofaringe, orofaringe e glândulas salivares. Não só o cancro oral produz alterações na cavidade oral, bem como a terapia utilizada para o tratamento dos diversos tipos de neoplasias. A radioterapia é uma das formas terapêuticas utilizada para o tratamento das neoplasias da cabeça e pescoço, porém apesar da sua eficácia esta modalidade terapêutica também promove alguns efeitos adversos, tais como a mucosite, xerostomia, dermatite, disfagia, disgeusia, infecções secundárias, cárie por radiação, trismo, necrose de tecido mole e osteorradionecrose. Estes efeitos colaterais decorrentes da radioterapia estão relacionados com a dose de radiação, a forma de administração, a extensão e a localização da área a ser irradiada, bem como a qualidade e poder de penetração da radiação e dos factores individuais do paciente. Deste modo, os danos da radiação podem manifestar-se gradualmente ao longo de muitos meses ou anos após o terminar do tratamento e/ou ocorrer meses depois do termino da terapia antitumoral. As complicações do cancro de cabeça e pescoço encontram-se entre as mais devastadoras a curto e a longo prazo, por afectarem as actividades humanas mais básicas, tais como alimentar-se e comunicar-se. Assim, é de grande importância que o Médico Dentista, a fim de minimizar os transtornos decorrentes da terapia antitumoral, examine o paciente antes de iniciar o tratamento antineoplásico, e inicie um programa de higiene oral e seja instruído sobre a importância desta higienização no decurso do tratamento oncológico. Assim sendo, é necessário uma equipa multidisciplinar, do qual o Médico Dentista faça parte, de modo a tornar mais digna a vida dos pacientes com este tipo de patologia, ou mesmo prevenir tais complicações surgidas devido à terapêutica. The head and neck cancer represents about 10% of malignant tumors worldwide, and are diagnosed annually substantially 500,000 new cases worldwide. Nationally, the head and neck cancer is a relatively common malignancy, accounting for a high mortality rate. In 2005 and 2006 were 10286 registered patients in RORENO, and of these, 1240 were related to the oral cavity and neck, and the main locations in the thyroid gland, followed by the larynx, esophagus, mouth (including gum, floor of mouth, palate and retromolar trigone), tongue, tonsil, lip, hypopharynx, nasopharynx, oropharynx and salivary glands. Not only oral cancer produces changes in the oral cavity as well as the therapy used for treating various types of neoplasms. Radiation therapy is one way used for the therapeutic treatment of cancers of head and neck, but despite its efficacy, this type of treatment also promotes some adverse effects, such as mucositis, xerostomia, dermatitis, dysphagia, dysgeusia, secondary infections, caries by radiation, trismus, soft tissue necrosis and osteoradionecrosis. These side effects resulting from radiotherapy are related to the radiation dose, the administration form, the extent and location of the area to be irradiated, and the quality and and the penetrating power of the radiation and the individual factors of the patient. This way, the radiation damage may occur gradually over many months or years after the end of the treatment and / or occur months after the end of antitumor therapy. Complications of head and neck cancers are among the most devastating in the short and long term, to affect the most basic human activities such as eating and communicating. Thus, it is very important that the dentist, in order to minimize the problems caused antitumor therapy, examine the patient before starting their treatment, and initiate a program of oral hygiene and instructed on the importance of hygiene during the cancer treatment. Therefore, it is necessary a multidisciplinary team, of which the dentist is an essential part, to make more worthy the life of patients with this type of pathology, or even prevent such complications arising due to therapy.
6
Carvalho, Filipa Baptista Neto Viegas de. "A terapêutica fotodinâmica nos tratamentos das lesões potencialmente malignas e cancro da cavidade oral." Master's thesis, [s.n.], 2015. http://hdl.handle.net/10284/5239.
Повний текст джерелаАнотація:
Projeto de Pós-Graduação/Dissertação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Mestre em Medicina DentáriaA terapia fotodinâmica (PDT, do inglês, photodynamic therapy) é uma opção terapêutica recente e valiosa, dirigida para a destruição das células tumorais, com potencial para ser incluída no tratamento principal de combate ao cancro, bem como adjuvante de outras terapêuticas. Atualmente é considerada uma estratégia terapêutica de sucesso, clinicamente, aprovada para o tratamento de lesões potencialmente malignas (LPM) e malignas da cavidade oral. A PDT envolve a administração de um fotossensibilizador (PS, do inglês, photosensitizer) que, por si só, não possui efeito farmacológico. Contudo, este é, posteriormente ativado por irradiação, com luz visível de comprimento de onda (λ) adequado ao local a tratar. Com a foto-ativação do PS ocorre a produção de espécies reativas de oxigénio (ROS, do inglês, reactive oxygen species) que dão inicio à morte celular. O processo está associado com a indução de uma forte reação inflamatória local, potenciando a resposta imunitária e conduzindo à destruição efetiva das células tumorais. O efeito citotóxico ocorre, apenas, no local de ativação da luz e o PS acumula-se preferencialmente nas células malignas, pelo que esta terapêutica apresenta elevada seletividade e um baixo número de efeitos secundários. No contexto clínico, a PDT é utilizada em diversas áreas da medicina como a oftalmologia, a dermatologia e a oncologia, entre outras. No entanto, a sua utilização no tratamento do cancro ainda é limitada.
Photodynamic therapy (PDT) is a new and valuable therapeutic option, directed to the destruction of tumor cells, with the potential to be included in the primary treatment to combat cancer, as well as an adjunct to other therapies. A successful therapeutic strategy, clinically approved for the treatment of premalignant lesions (LPM) and malignant oral cavity is considered currently. PDT involves the administration of a photosensitizer (PS) which, by itself, does not possess pharmacological effect. However, this is subsequently activated by irradiation with visible light of wavelength (λ) appropriate to the site to be treated. With the photo-activation of the PS occurs the production of reactive oxygen species (ROS, English, reactive oxygen species) that give beginning to cell death. The process is associated with the induction of a strong local inflammatory response, enhancing the immune response and leading to the effective destruction of tumor cells. The cytotoxic effect occurs only in the light activation site and the PS accumulates preferentially in malignant cells, whereby this treatment has high selectivity and a low number of side effects. In the clinical context, PDT is used in many areas of medicine such as ophthalmology, dermatology and oncology, among others. However, their use in cancer treatment is still limited.
7
Khaw, Arlene Bee Hong. "Influence of periodontitis on the experience of oral mucositis in cancer patients undergoing head and neck radiotherapy." Thesis, 2014. http://hdl.handle.net/2440/83794.
Повний текст джерелаАнотація:
Background and aim: Virtually all patients who receive head and neck radiotherapy develop some degree of oral mucositis. Severe oral mucositis may necessitate an interruption of the course of radiotherapy and thus can serve as a dose-limiting factor. Periodontitis is a host-driven inflammatory response to a pathogenic bacterial biofilm in the subgingival environment, resulting in the progressive destruction of the tissues that support the teeth, specifically the gingiva, periodontal ligament, and alveolar bone. This disease affects more than 50% of the population. Considering that radiation-induced oral mucositis and periodontitis are both characterised by the continuing presence of systemic inflammation, they may be associated through a primed inflammatory response as proposed by the “two-hit” model. Alternatively, both conditions may be correlated as they represent a dysregulation of the inflammatory response. To date, no studies have looked into the association between these conditions. The aim of this study is to determine whether the severity of oral mucositis is associated with the severity of periodontitis in cancer patients undergoing head and neck radiotherapy. Materials and methods: Eighty-five consecutive patients seeking dental clearance prior to head and neck radiotherapy were assessed for their eligibility for participation in the study. Forty-one patients met the inclusion criteria. The severity of oral mucositis was measured according to the WHO system. The severity of periodontitis was assessed clinically and radiographically. Gingival crevicular fluid was sampled and levels of eight cytokines were determined using a multiplexed bead immunoassay. The association between radiation-induced oral mucositis and periodontitis was analysed using logistic and linear regression, and two-way contingency tables. Results: The mean age of the whole study population was 63.3 ± 11.0 years (range 44.8 to 82.9 years). The majority of patients were male (73%). The primary tumour site was most commonly the oral cavity and salivary gland (45%), followed by the pharynx (33%) and larynx and others (21%). The duration of radiotherapy was significantly associated with the severity of oral mucositis (p-value=0.038). A trend towards increased pocket depth and clinical attachment levels was noted in patients with oral mucositis grades 1-4, but this was not statistically significant. Conclusion: Patients seeking dental clearance prior to head and neck radiotherapy at the Special Needs Unit, Adelaide Dental Hospital, were a good representation of the general head and neck cancer population. The resultant lack of association between radiation-induced oral mucositis and periodontitis was attributed to the extraction of teeth prior to periodontal examination, lack of uniformity of cancer treatment regimens and lack of statistical power. Hence, larger studies with a tighter inclusion criteria (e.g. similar radiotherapy protocol, without chemotherapy or surgery) are now required to follow-up on these preliminary findings.Thesis (D.Clin.Dent.) -- University of Adelaide, School of Dentistry, 2014
8
Bowen, Joanne. "Prevention of oral mucositis in head and neck cancer patients : a systematic review." Thesis, 2012. http://hdl.handle.net/2440/78862.
Повний текст джерелаАнотація:
Oral mucositis is a common and costly consequence of cancer treatment that currently lacks adequate intervention options. Patients treated for head and neck malignancies are at particularly high risk of severe mucositis, which significantly impedes delivery of therapy and consequently results in poorer outcomes in this population. As such, the quantitative objective of this review was to identify the effectiveness of agents and devices for oral mucositis prevention in newly diagnosed adult head & neck cancer patients being treated with radiotherapy with or without chemotherapy. The methodological framework developed by the Joanna Briggs Institute was followed to conduct the review. The quantitative component of the review considered any randomised controlled trials. In the absence of RCTs other research designs, such as non-randomised controlled trials and before and after studies, were considered for inclusion in a narrative summary to enable the identification of current best evidence. Databases were searched for published and non-published studies. A total of 202 studies were retrieved for review, with 81 studies excluded after reading the full article for clearly not meeting the inclusion criteria of the review. Two reviewers independently assessed 123 studies for methodological quality, excluding 51 for a range of reasons including failure to present baseline data, and use of intervention for mucositis treatment rather than prophylaxis. In the final 72 studies, 13 interventions provided sufficient evidence to be combined in meta-analyses. Only 8 interventions provided weak evidence of benefit to prevent oral mucositis in head and neck cancer patients treated with radiotherapy, with or without chemotherapy, including amifsotine (intravenous administration), aloe vera, G-CSF, honey, sucralfate, morning radiotherapy, providone-iodine and Wobe-Mugos E. Honey was the only intervention to significantly reduce severe mucositis during radiotherapy in all studies, indicating that this is a promising agent deserving further investigation. The remaining interventions had either too few studies conducted or conflicting results to make conclusions regarding effectiveness. A lack of studies which examined the same intervention and inconsistency in reporting of outcomes prevented aggregation of study results into statistical meta-analysis for most interventions. Furthermore, a general need for additional well designed, adequately powered studies of interventions contributed to the lack of evidence. Future mucositis intervention studies require appropriate placebo controls and double blinding to increase the level of evidence available for the few promising interventions identified.Thesis (M.Phil.) -- University of Adelaide, The Joanna Briggs Institute, 2012
9
Huang, Yi Ying, and 黃怡螢. "Impact of Oral Care on Oral Mucositis and Quality of Life for Head and Neck Cancer Patients during Radiotherapy." Thesis, 2013. http://ndltd.ncl.edu.tw/handle/e4sa4b.
Повний текст джерела
10
Al-Qadami, Ghanyah Hamid Hussein. "Exploring the Role of the Gut Microbiome in Toxicity and Response to Radiotherapy for Head and Neck Cancer." Thesis, 2021. https://hdl.handle.net/2440/135226.
Повний текст джерелаАнотація:
Radiotherapy is a mainstay treatment modality used for the treatment of more than 80% of patients with head and neck cancer (HNC). Despite the technological advances in radiotherapy delivery, two key limitations remain a challenge for HNC radiotherapy. First, HNC radiotherapy is associated with unacceptable levels of normal tissue toxicities. One of the most frequent and troublesome toxicities is oral mucositis (OM). Radiotherapy-induced OM refers to the inflammation and/or ulceration of the oral mucosa following radiotherapy. It can affect more than 90% of patients with HNC, with varying degrees of severity. The major challenges related to OM are the lack of effective interventions to prevent or treat OM and the lack of a robust predictive marker to predict OM risk. The second limitation of HNC radiotherapy is heterogeneity in patients' response in terms of tumour control and recurrence. Currently, there are no biomarkers to identify patients with a favourable response and those at risk for primary tumour failure or tumour recurrence. Therefore, finding new targets for OM interventions and predictive biomarkers to predict radiotherapy outcomes will help address these limitations of HNC radiotherapy and improve treatment success. Recent years have witnessed a growing interest in the role of the gut microbiome in cancer treatment efficacy and toxicity, including radiotherapy. The gut microbiome, a collection of microorganisms residing in the gastrointestinal tract, plays a central role in the modulation of systemic immune and inflammatory responses. Given that OM is an inflammatory condition and radiotherapy-induced immunogenic cell death is a key pathway by which radiotherapy kills tumour cells, we hypothesised that the gut microbiome may influence both the pathogenesis of OM and radiotherapy response through modulation of immune and inflammatory signalling. As such, this thesis aimed to investigate the impact of the gut microbiome on the development of radiotherapy-induced OM and radiotherapy outcomes in preclinical and clinical settings. Firstly, I investigated this in preclinical studies described in chapters 3-5. In chapter 3, I successfully developed an antibiotic-induced gut microbiota depletion (AIMD) method that allows for studying the development of OM in the absence of major bacterial taxa. In chapter 4, I established a radiation-induced OM model in rats using a single radiation dose of 20 Gy. These two models were used to conduct the main animal study (chapter 5), which demonstrated that the gut microbiome is involved in the pathogenesis of OM, particularly the healing stage, through the modulation of inflammatory cytokines. Lastly, to translate my preclinical findings to the clinical settings, I investigated whether patient pre-treatment gut microbiome is associated with the severity of OM and radiotherapy response in patients with HNC (chapter 6). The results from this clinical study showed that certain microbes in the baseline gut microbiome are associated with OM severity and tumour recurrence. Together, the results from this thesis suggest that the gut microbiome is involved in the pathogenesis of OM and is associated with radiotherapy response offering a potential target to treat or prevent OM and predict treatment outcomes.Thesis (Ph.D.) -- University of Adelaide, School of Biomedicine, 2021
Тези доповідей конференцій з теми "Periodontitis; oral mucositis; head and neck radiotherapy"
1
Gu, Fangyi, William D. Duncan, YingDong Feng, Austin Miller, Nicolas Schlecht, Alan Hutson, and Anurag K. Singh. "Abstract 4860: Association between timing of radiotherapy and severity of oral mucositis in head-neck cancer patients." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4860.
Повний текст джерела
2
Gu, Fangyi, William D. Duncan, YingDong Feng, Austin Miller, Nicolas Schlecht, Alan Hutson, and Anurag K. Singh. "Abstract 4860: Association between timing of radiotherapy and severity of oral mucositis in head-neck cancer patients." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4860.
Повний текст джерела
3
Lin, Hongying, Min Ma, and Shengcun Zhang. "The Clinical Analysis on Acute Oral Cavity Mucositis Caused by the Radiotherapy for the Head and Neck Cancer." In 2015 International Forum on Bioinformatics and Medical Engineering. Paris, France: Atlantis Press, 2015. http://dx.doi.org/10.2991/bme-15.2015.5.
Повний текст джерела
4
Hahn Kakas Galassi, Victória, MARY ANN FOGLIO, Michelle P. Jorge, Ilza M. O. Souza, Nubia Cassia Queiroz, and CARMEN S. P. LIMA. "Evaluation of life quality in pacients with head and neck squamous cells carcinome before and after the appereance of Oral Mucositis (OM) caused by chemiotherapy treatment with Cisplatin associated with Radiotherapy: Relation of the Presence and Level of OM in second phase clinical study comparing the treatment of OM between a phytotherapic and application of low intensity laser." In XXV Congresso de Iniciação Cientifica da Unicamp. Campinas - SP, Brazil: Galoa, 2017. http://dx.doi.org/10.19146/pibic-2017-78218.
Повний текст джерела